HK

Hemant Kumar

Director Director DIN 07871984
DIN 07871984 First appointment Jun 2017 Primary industry Trading
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Jun 2017
Shareholding value β€’β€’β€’β€’ Premium profile

About Hemant Kumar

Data last updated:

Hemant Kumar was a Director at Nexgen Bio Sciences Private Limited (2017–2024) and Director at Medberg Pharma Private Limited (from 2017). The companies operate in Trading.

DIN 07871984
Primary Designation Director
Industry Trading
First Appointment 19 Jun 2017
Oldest Company Age 12 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Nexgen Bio Sciences Private Limited U51909JH2010PTC014340
Director19 Jun 20172010₹1.64 Cr (FY 2025)Active
Medberg Pharma Private Limited U24233MH2014PTC258694
Director26 Dec 20172014₹1.3 Lakh (FY 2017)Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Medberg Pharma Private Limited
Nexgen Bio Sciences Private Limited
Premium access

Shareholding and investment profile for Hemant Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hemant Kumar

Hemant Kumar was first appointed on 19 Jun 2017 as Director at Nexgen Bio Sciences Private Limited.

Hemant Kumar held 2 earlier board appointments: Nexgen Bio Sciences Private Limited (Director, 19 Jun 2017 to 25 Sep 2024); Medberg Pharma Private Limited (Director, from 26 Dec 2017).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available